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Abstract
Objective
To investigate the sensitivity and the speciﬁcity of serum vascular endothelial growth factor
(sVEGF) for the diagnosis of polyneuropathy, organomegaly, endocrinopathy, M-protein, and
skin changes (POEMS) syndrome in patients with a neuropathy (NP) and to identify con-
founding causes of raised vascular endothelial growth factor (VEGF) in this context to improve
accuracy.
Methods
We studied the speciﬁcity and sensitivity of sVEGF for the diagnosis of POEMS syndrome in
a cohort of 195 consecutive patients with anNP in serum samples from June 2009 toNovember
2013, including 27 untreated patients with POEMS syndrome. We then studied VEGF in other
neuropathies and analyzed causes of elevated VEGF in a multiple logistic regression analysis in
a larger cohort of 236 patients including 168 with a non-POEMS NP and 68 without NP.
Results
The sensitivity of elevated sVEGF for the diagnosis of POEMS was 100%. Its speciﬁcity was
91% in patients with an NP and 92% in patients with an NP and a paraproteinemia. sVEGF was
much higher in POEMS before treatment. sVEGF was not signiﬁcantly elevated in any non-
POEMS NP or hematologic disease group. Multiple logistic regression showed that anemia
with low iron was a signiﬁcant predictor for elevated sVEGF and that chronic obstructive
pulmonary disease (COPD) and obstructive sleep apnoea-hypopnoea syndrome were signif-
icant predictors for very elevated sVEGF.
Interpretation
We conﬁrmed the high sensitivity and speciﬁcity of an elevated VEGF for the diagnosis of
POEMS. However, VEGF testing should be repeated, particularly after acute illnesses. Raised
sVEGF should be interpreted with caution unless anemias with low iron, sleep apnea, COPD,
cancers, vasculitis, and chronic inﬂammatory diseases are excluded.
Classification of evidence
This study provides class IV evidence that elevated sVEGF levels accurately identiﬁes patients
with POEMS syndrome.
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Polyneuropathy, organomegaly, endocrinopathy, M-protein,
and skin changes (POEMS) syndrome is a rare and severe
multisystem disease driven by an underlying plasma cell dys-
crasia. Treatments include surgical removal or irradiation of
isolated plasmacytoma and, when the plasma cell dyscrasia is
disseminated, chemotherapy with or without hematopoietic
stem cell transplantation.1 Raised circulating vascular endothe-
lial growth factor (VEGF) levels have been reported in patients
with POEMS.2–4 Because this appears to be a distinct charac-
teristic from other paraproteinemic neuropathies, the diagnostic
criteria for POEMSweremodiﬁed in 2007 to include circulating
VEGF as a major criterion.5 POEMS syndrome is conﬁrmed
when the 2 mandatory criteria of a polyneuropathy and a
monoclonal plasma cell proliferative disorder are present, in
association with at least one of the other major criteria (Cas-
tleman disease, sclerotic bone lesion(s), and VEGF elevation),
and with at least one of the minor diagnostic criteria.5 Levels of
circulating VEGF are also probably useful in the follow-up of
patients with POEMS syndrome as a biomarker of response to
treatment.4,6 However, elevated VEGF has been described in
diseases other than POEMS4,7 and patients with a neuropathy
(NP) and a paraproteinemia, and failure to respect this could
potentially lead to an incorrect diagnosis of POEMS syndrome.
This study documents the speciﬁcity (Sp) and sensitivity (Se)
of serum VEGF (sVEGF) for the diagnosis of POEMS syn-
drome in a retrospective cohort of patients with an NP and
identifying confounding factors of raised sVEGF in the in-
vestigation of neuropathies with paraproteinemia.
Methods
The primary research questions to address in this study were
as follows:
1. What is the sensitivity and speciﬁcity of raised sVEGF for
the diagnosis of POEMS syndrome compared with other
causes of NP or non-POEMS hematologic disease (HD)?
2. What confounding factors cause raised sVEGF?
This retrospective study included consecutive patients attending
peripheral nerve outpatient clinics at the National Hospital for
Neurology and Neurosurgery who had an sVEGF tested as part
of their clinical investigations from June 2009 to November
2013. Samples were sent immediately for processing in the
Neuroimmunology Department of the Institute of Neurology,
Queen Square, London, United Kingdom. Only patients with
available clinical data were included in the study. We collected
their age, sex, and pathologic conditions at the time of sVEGF
testing from their medical records. The cohort included both
POEMS and non-POEMS patients. Patients with POEMS
syndrome were diagnosed according to internationally accepted
criteria1; all had a polyneuropathy, and a monoclonal plasma cell
disorder identiﬁed on serologic testing, bone marrow biopsy
with or without plasmacytoma histology. Serial testing was
requested in some because levels of VEGF were high and un-
explained or lower than expected when POEMS was suspected.
Because the purpose of this study was to identify and explain the
causation of increased VEGF levels in non-POEMS patients, the
highest values in all patients were selected.
sVEGF levels were measured by commercial ELISA according
to the manufacturer’s instructions (R&D Systems, Minne-
apolis, MI). The upper limit of the normal range was de-
termined as 90% ﬁt of sera from 108 normal healthy blood
donors and was 771 pg/mL. Current practice in hematology
uses a cutoﬀ of 1,000 pg/mL as a more signiﬁcant elevation of
sVEGF. In this study, sVEGF was considered as “elevated”
when ≥771 pg/mL and “very elevated” when ≥1,000 pg/mL.
IBM SPSS Statistics 21 was used for statistical analysis. Non-
parametric tests (Mann-Whitney U and Kruskal-Wallis) were
used to compare sVEGF levels between groups and subgroups of
disease because sVEGF values were not normally distributed,
and some groups or subgroups had small numbers of patients.
The Spearman correlation test was used for correlations between
sVEGF and age. Chi-square tests were used to compare the
frequency of elevated and very elevated sVEGF in the diﬀerent
groups of diseases. Multiple logistic regression analyses were
used to identify independent risks factors for elevated and very
elevated sVEGF in the non-POEMS patient population.
Standard protocol approvals, registrations,
and patient consents
Ethics committee approval was not required for this labora-
tory audit and clinical assay development. Studies of this kind
are approved under The Royal College of Pathologists guid-
ance. All patient information is fully anonymized.
Data availability
Any anonymized data not published within the article will be
shared by request from a qualiﬁed investigator.
Results
A total of 206 patients with an NP had at least 1 test for sVEGF.
There were 70 women (34%) and 136 men (66%) aged 58.4 ±
Glossary
COPD = chronic obstructive pulmonary disease; HD = hematologic disease; Ig = immunoglobulin; IL-6 = interleukin 6;
OSAHS = obstructive sleep apnoea-hypopnoea syndrome; NP = neuropathy; POEMS = polyneuropathy, organomegaly,
endocrinopathy, M-protein, and skin changes; sVEGF = serum vascular endothelial growth factor; VEGF = vascular endothelial
growth factor; WM = Waldenstro¨m macroglobulinemia.
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14.3 years (mean ± SD, range 19–92 years). Thirty-eight
patients had clinically conﬁrmed POEMS syndrome fulﬁlled by
criteria other than increased VEGF levels, including 27 pre-
treatment and 11 posttreatment POEMS cases, and 168
patients had non-POEMS NP (table 1). Of the 11 treated
patients with POEMS syndrome, 6 had received an autologous
bone marrow transplant, 2 radiotherapy, 2 cyclophosphamide/
dexamethasone, and 1 lenalidomide/dexamethasone.
sVEGF in patients with neuropathy
sVEGF was signiﬁcantly higher in the pretreatment POEMS
group than in any of the other NP groups (p < 0.0001). It was
also higher in the posttreatment POEMS, CIDP, and anti-
MAG NP groups than in the other noninﬂammatory NP
groups (p = 0.013, p = 0.023, and p = 0.009), and it was higher
in the posttreatment POEMS and anti-MAG NP groups than
in the other inﬂammatory and paraproteinemic NP groups
(p = 0.039 and p = 0.025) (table 1, ﬁgure 1).
All the pretreatment POEMS patients had very elevated
sVEGF concentrations (p < 0.0001 in comparison to other
NP groups). The anti-MAG NP group had also a larger
proportion of patients with elevated and very elevated
sVEGF than CIDP, other inﬂammatory/paraproteinemic,
and other noninﬂammatory NP groups (p < 0.05). Apart
from the anti-MAG NP group (p = 0.447 vs posttreatment
POEMS), more patients in the posttreatment POEMS
group had an elevated sVEGF than in the other non-POEMS
NP groups (p < 0.05), which was not found with very ele-
vated sVEGF (table 1).
sVEGF concentrations and the frequency of patients
with raised sVEGF did not diﬀer between the subgroups of
the other inﬂammatory and paraproteinemic NPs (p =
0.924), nor between the subgroups of other non-
inﬂammatory NPs (p = 0.392) (table e-1, links.lww.com/
NXI/A61).
Table 1 sVEGF concentrations and proportion of patients with raised sVEGF in the NP and hematologic disease groups
(N = 206 patients)
N patients (%)
sVEGF (pg/mL)
Mean ± SD
Median [minimum;
maximum]
>771 >1,000
N % gpa N % gp
POEMS syndrome 38 (18.4%) 2,741 ± 2,652 1,934 [30; 10,956] 32 84.2 28 73.7
Pretreatment 27 (13.1%) 3,506 ± 2,717 2,030 [1,010; 10,956] 27 100 27 100
Posttreatment 11 (5.3%) 864 ± 1,170 717 [30; 4,247] 5 45.5 1 9.1
Non-POEMS NP 168 (81.6%) 364 ± 324 234 [19; 2,616] 15 8.9 11 6.5
CIDP 51 (24.8%) 406 ± 492 271 [41; 2,616] 4 7.8 2 3.9
Anti-MAG NPb 19 (9.2%) 566 ± 503 370 [59; 1,743] 6 31.6 5 26.3
Vasculitic NPb 12 (5.8%) 450 ± 601 309 [54; 2,261] 1 8.3 1 8.3
Other inflammatory and paraproteinemic NPs 33 (16.0%) 309 ± 341 209 [34; 1,816] 2 6.1 1 3.0
Other noninflammatory NPs 55 (26.7%) 261 ± 278 153 [19; 1,469] 2 3.6 2 3.6
Non-POEMS hematologic disease 88 (42.7%) 356 ± 372 234 [28; 1,816] 8 9.1 7 8.0
MGUS 54 (26.2%) 376 ± 374 272 [34; 1,743] 5 9.3 4 7.4
Multiple myeloma 18 (8.7%) 190 ± 171 105 [28; 547] 0 0 0 0
Other 16 (7.8%) 475 ± 475 363 [34; 1,816] 3 18.8 3 18.8
Waldenstrom macroglobulinemia 9 (4.4%) 517 ± 349 460 [53; 1,069] 2 22.2 2 22.2
Non-Hodgkin lymphomac 4 (1.9%) 546 ± 850 168 [34; 1,816] 1 25 1 25
Other hematologic malignanciesd 3 (1.5%) 254 ± 182 230 [86; 447] 0 0 0 0
No hematologic disease 80 (38.8%) 373 ± 477 232 [19; 2,616] 7 8.8 4 5.0
Total 206 (100%) 803 ± 1,507 311 [19; 10,956] 47 22.8 39 18.9
Abbreviations: Anti-MAG = anti-myelin-associated glycoprotein; MGUS= monoclonal gammopathy of unknown significance; NP = neuropathy; POEMS =
polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes; sVEGF = serum vascular endothelial growth factor.
a Percentage of patients with increased VEGF levels in the disease group.
b Two patients with anti-MAG and vasculitic neuropathy.
c Follicular NHL (n = 1), Burkitt NHL (n = 1), and low-grade B-cell NHL (n = 2).
d Chronic lymphoid leukemia (n = 1), chronic myeloid leukemia (n = 1), and indolent T-cell large granular lymphocyte leukemia (n = 1).
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sVEGF in patients with hematologic disease
Eighty-eight of 168 non-POEMS NP patients had a HD not
always related to their NP (table 1). One patient with pre-
treatment POEMS syndrome had a nonsecretory monoclonal
plasma cell disorder conﬁrmed on bone marrow biopsy.
sVEGF was signiﬁcantly higher in the pretreatment POEMS
than in the other HD groups (p < 0.01). Posttreatment
POEMS had higher sVEGF than the multiple myeloma and
no HD groups (p < 0.05) and similar sVEGF than the other
HD groups. sVEGF concentrations were lower in the multiple
myeloma group than in the pre- and post-treatment POEMS,
MGUS, and Waldenstro¨m macroglobulinemia (WM) groups
(p < 0.05), and it also tended to be lower than in the no HD
group (p = 0.052).
Sensitivity and specificity of sVEGF in
POEMS syndrome
For the Se-Sp study of sVEGF for the diagnosis of POEMS
syndrome, posttreatment POEMS was excluded. This was
studied in 195 patients with an NP (table 2). The area under
the receiver operating characteristic curve (area under the
curve (AUC) ± standard error [95% CI (CI)]) was 0.985 ±
0.07 (0.971–0.998). In a subgroup of 109 patients with an NP
and a paraproteinemia, i.e., who had the 2 mandatory major
criteria for the diagnosis of POEMS syndrome5 (table 2), the
AUC was 0.993 ± 0.005 (0.983–1.000).
Fifteen of 206 patients had a non-POEMS NP and a raised
sVEGF, including 7 patientswith a paraprotein (ﬁgure 2, table e-2,
links.lww.com/NXI/A61). The mean ± SD number of comor-
bidities per patient was 2.9 ± 1.5 (median 3.0, range 1–7). The
number of comorbidities was not correlated with sVEGF con-
centrations (rs = −0.09, p = 0.246). There was no sex (p = 0.845)
or age (rs = −0.035, p = 0.653) eﬀect on sVEGF concentrations.
To further explain sVEGF elevation in those 15 patients with
a non-POEMS NP and a raised sVEGF, all other comorbidities
at the time of sVEGF testing were explored as potential con-
founding factors. Those analyses did not include patients with
POEMS and thus explored 168 patients. Comorbidities were
anemia (n = 20), diabetes (n = 18), chronic inﬂammatory dis-
ease (n = 12), ischemic disease (peripheral and coronary arterial
diseases and stroke) (n = 11), solid cancer (n = 5), hypoxemic
disease (chronic obstructive pulmonary disease [COPD], and
obstructive sleep apnoea-hypopnoea syndrome [OSAHS]) (n =
10), hypertension (n = 47), other neurologic diseases (n = 14),
other endocrinopathy (n = 13), benign tumurs (n = 11), dysli-
pidemia (n = 11), asthma (n = 9), nonischemic heart disease (n
= 8), osteoporosis (n = 8), chronic kidney disease (n = 5), and
miscellaneous conditions (n = 29).
Anemia was deﬁned as hemoglobin ≤12 g/dL (n = 20/168;
11.9%). There was no signiﬁcant diﬀerence in sVEGF
Figure 1 Serum vascular endothelial growth factor (sVEGF) concentrations in different NP groups
1,000 pg/mL (very elevated sVEGF); 771 pg/mL (elevated sVEGF). *p < 0.0001 in comparison with each other group; **p < 0.05 in comparison with other
inflammatory/paraproteinemic NPs and other noninflammatory NPs; ***p < 0.05 in comparison with other noninflammatory NPs. Anti-MAG = anti-myelin-
associated glycoprotein; CIDP = chronic inflammatory demyelinating polyneuropathy; NP = neuropathy; POEMS = polyneuropathy, organomegaly, endo-
crinopathy, M-protein, and skin changes; VEGF = vascular endothelial growth factor.
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concentrations in patients with anemia (median [min; max]:
331 [28; 2,616] pg/mL) or without anemia (229 [19; 2,443])
(p = 0.428). However, when subgroups of anemia were de-
ﬁned according to their serum iron concentrations, there was
a signiﬁcant diﬀerence (p = 0.017): sVEGF concentrations
were signiﬁcantly elevated in patients with anemia and low
serum iron (789 [320; 2,616] pg/mL, n = 5) in comparison to
patients without anemia (229 [19; 2,443] pg/mL, n = 148)
(p = 0.005) and with anemia and normal serum iron (175 [28;
1,816] pg/mL, n = 15) (p = 0.029). Of the 5 patients with
anemia and low serum iron, 3 had CIDP, one an anti-MAG
NP, and 1 vasculitic NP. The clinical data of these 5 cases are
summarized in table e-4, links.lww.com/NXI/A61. sVEGF
concentrations did not diﬀer in the low serum iron subgroup
whether the iron proﬁle showed an iron deﬁciency (n = 2) or
a chronic inﬂammation pattern (n = 3). Ten (6%) patients
had a hypoxemic disease, 4 with COPD, and 6 with OSAHS.
Although the mean sVEGF concentrations were not signiﬁ-
cantly diﬀerent between patients with (291 [69; 2,443]
pg/mL) and without hypoxemic disease (229 [19; 1,616])
(p = 0.400), the proportion of patients with a very elevated
sVEGF was higher in patients with OSAHS representing 2/10
Table 2 Sensitivity and specificity of sVEGF for the diagnosis of POEMS syndrome in patients with an NP
sVEGF (pg/mL) Se Sp NPV PPV
NP (N = 195) >771 100% 91% 100% 64%
>1,000 100% 93% 100% 71%
NP and paraproteinemia (N = 109) >771 100% 92% 100% 79%
>1,000 100% 93% 100% 81%
Abbreviations: NP = neuropathy; NPV = negative predictive value; POEMS = polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes;
PPV = positive predictive value; Se = sensitivity; Sp = specificity; sVEGF = serum vascular endothelial growth factor.
NP: posttreatment POEMS excluded (n = 11); sVEGF > 771 pg/mL: elevated sVEGF; sVEGF >1,000 pg/mL: very elevated sVEGF.
Figure 2 Distribution of serum vascular endothelial growth factor (sVEGF) in different neuropathy groups
1,000 pg/mL (very elevated sVEGF); 771 pg/
mL (elevated sVEGF). Anti-MAG= anti-myelin-
associated glycoprotein; CIDP = chronic in-
flammatory demyelinating polyneuropathy;
NP = neuropathy; POEMS = polyneuropathy,
organomegaly, endocrinopathy, M-protein,
and skin changes; VEGF = vascular endothe-
lial growth factor.
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(20.0%) than in patients without a hypoxemic disease (9/158,
5.7%) (p = 0.023). All 4 COPD patients had a stable disease
without any recent exacerbation. Two of 6 patients with
OSAHS were untreated at the time of testing and had a par-
ticularly high sVEGF concentration (1,043 and 2,443 pg/
mL). No other comorbidities were associated with raised
sVEGF concentration.
Because patients had multiple comorbidities, we explored risk
factors for raised sVEGF with multiple logistic regression
analyses. As some disease groups had small numbers of
patients, we included 68 consecutive patients without an NP
for whom sVEGF testing was requested between June 2009
and November 2013 and for whom clinical data were avail-
able. Thus, a total of 236 patients were analyzed. Twenty-
three of 236 patients (9.7%) had an elevated sVEGF (8
without an NP), and 13/236 (5.5%) had a very elevated
sVEGF (2 without a NP). In addition to the non-POEMS NP
and the HDs groups, the variables assessed for their predictive
value are set out in table e-3, links.lww.com/NXI/A61, the
most common of which were hypertension (n = 59), diabetes
(n = 23), other endocrinopathies (n = 20), anemia with
normal serum iron (n = 32) and with low serum iron (n = 6),
other neurologic diseases (n = 26), and chronic inﬂammatory
diseases (n = 23). The ﬁrst model assessed the risk of any
comorbidity for an “elevated” sVEGF. Anemia with low iron
was the only signiﬁcant predictor with an OR of 15.4 (95% CI
1.3–187.8 [p = 0.032]) (ﬁgure 3). In addition, there was
a trend for COPDorOSAHS (OR= 7.9, 95%CI 0.8–81.0, p =
0.081) and anti-MAG NP (OR = 8.6, 95% CI 0.98–75.6,
p = 0.052) to be predictive of elevated sVEGF. The second
model assessed the risk of having a “very elevated” sVEGF.
Here, OSAHS or COPD was the only signiﬁcant predictive
factor (OR = 41.7, 95% CI 1.4–1,226, p = 0.031) (ﬁgure 3).
Discussion
This retrospective study conﬁrms the high speciﬁcity and
sensitivity of VEGF for the diagnosis of POEMS syndrome,
especially when it is raised in the presence of an NP and
a paraproteinemia. Similar ﬁndings using plasma VEGF in
a cohort of 105 patients have also been demonstrated.4 By
selecting patients with an NP, i.e., a population with a clinical
presentation more such as POEMS syndrome and thus more
likely to be tested, our study found a higher Sp and Se. This
highlights the advantages of testing in a targeted population. A
larger number of patients may also contribute to the accuracy
of Sp and Se. The use of plasma vs sVEGF is discussed. Higher
concentrations of sVEGF reﬂect the release of VEGF from
platelets during aggregation, and this could lead to a lack of
reliability of sVEGF depending on collection and processing
procedures.1 However, variations of plasma VEGF can also
occur depending on those procedures, and standardization is
needed for both plasma and serum testing.8 sVEGF might
better reﬂect the VEGF overproduction in pathologic con-
ditions and should probably be interpreted together with the
platelet count.9 Timing of blood collection to processing was
not standardized in this retrospective study, which could aﬀect
Figure 3 sVEGF concentrations in anemia and hypoxemic diseases
(A) Serum VEGF in anemia with and without iron deficiency. (B) Serum VEGF in hypoxemic diseases. 1,000 pg/mL (very elevated sVEGF); 771 pg/mL
(elevated sVEGF). COPD = chronic obstructive pulmonary disease; OSAHS = obstructive sleep apnoea-hypopnea syndrome; sVEGF = serum vascular
endothelial growth factor.
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the recorded sVEGF level. In another published cohort of 161
patients with an NP, lower speciﬁcity and positive predictive
values were found, but 29 patients with amyotrophic lateral
sclerosis were included.10 The proportions of patients with
elevated sVEGF in the anti-myelin-associated glycoprotein
(anti-MAG) NP, multifocal motor neuropathy (MMN), and
other noninﬂammatory NP groups are similar to other
studies.4,10 Higher sVEGF levels in patients with chronic in-
ﬂammatory demyelinating polyradiculoneuropathy (CIDP)
and Guillain-Barre´ Syndrome were not replicated in this
study. This discrepancy might be at least partially explained by
confounding comorbidities not explored in that study. In our
study, none of the NP groups was found to be an independent
predictive factor for raised sVEGF. However, comparative
tests and the multiple logistic regression analysis support
a raised sVEGF in some anti-MAG NPs, which requires
conﬁrmation by other studies. A raised sVEGF in this de-
myelinating NP associated with a paraproteinemia might lead
to a type I error. However, the clinical presentation, pro-
gression, and the associated HD are so diﬀerent that this
misdiagnosis is unlikely. Anti-MAGNP is only associated with
an immunoglobulin (Ig) M paraprotein usually with a kappa
light chain; it is incredibly rare to have an IgM paraprotein
associated with POEMS syndrome (2%, of cases, compared
with IgA [52%] or IgG [42%]11). Finding an increased VEGF
level, coupled with polyneuropathy and a non-IgM mono-
clonal paraprotein, especially with a lambda light chain,
should be considered highly likely to be POEMS syndrome.
As expected, all pretreatment POEMS patients had very ele-
vated sVEGF, signiﬁcantly higher than in the other NP and
HD groups. We did not look systematically at longitudinal
sVEGF progression after treatment. However, the mean
sVEGF was much lower in the posttreatment POEMS group,
in line with previous studies that showed a VEGF decrease in
response to treatment.3,4,6
No independent HD was associated with an elevated or very
elevated VEGF in the absence of POEMS. Angiogenesis factors
are involved in the pathogenesis of most of the hematologic
malignancies, and raised circulating VEGF levels have been de-
scribed in chronic myeloid leukemia, chronic myelomonocytic
leukemia, chronic lymphocytic leukemia, and lymphoma, often
in correlation with disease activity.12–14 The VEGF level has
previously been found elevated in multiple myeloma (MM),15
but our study found lower sVEGF concentrations in this group
in comparison to other HD groups and to patients with no
HD; this ﬁnding might be due to a large proportion (16/18) of
treated patients in our cohort.15 Increased VEGF levels has also
been described inWM in 1 study.16 However, even if VEGFwas
higher in WM than in other HD groups, this did not reach
signiﬁcance here, and WM was not identiﬁed as a predictor of
raised sVEGF in the multiple logistic regression models.
Anemia with low serum iron is a risk factor for elevated sVEGF.
The small number of patients in this subgroup results in a wide
CI, but as anemia can lead to tissue hypoxia and stimulate VEGF
secretion via hypoxia-inducible factor (HIF)-1-alpha stabiliza-
tion, it is a plausible cause of raised circulating VEGF.7,17 We
could observe a signiﬁcant decrease in sVEGF concentrations
from 2,616 to 800 pg/mL after iron supplementation in a CIDP
patient with iron deﬁciency anemia (patient 81, table e-2, links.
lww.com/NXI/A61). The association between increased VEGF
levels and low hemoglobin levels has mainly been studied in
patients with various cancers, and contradictory results were
found.18,19 In our cohort, anemia on its own was not found to
increase sVEGF levels, but it only became signiﬁcant when as-
sociated with low serum iron. The eﬀect of cellular iron de-
ﬁciency on VEGF production has been demonstrated in breast
cancer, supporting our results. This demonstrates in vitro that
intracellular iron deﬁciency, independent fromhypoxia, stabilizes
HIF-1-alpha, which increases the production of VEGF.20 The
upregulation of circulating VEGF secondary to iron deﬁciency
has then been demonstrated in mouse studies.21
COPD and OSAHS are very signiﬁcant risk factors for very
elevated sVEGF. The multiple logistic regression model in-
cluded 7 patients with a COPD and 7 with an OSAHS. The
4 patients with raised sVEGF had either untreated sleep
apnea (n = 2) or exacerbations of COPD (n = 2) (ﬁgure 3).
Increased VEGF levels has been described in patients withmild
to very severe COPD.22,23 Supporting our results, increased
VEGF levels has been demonstrated in COPD exacerbations,
correlated with systemic inﬂammatory markers, in comparison
to stable COPD and healthy subjects, which has been also
correlated inversely to arterial oxygenation.22,23 In OSAHS,
previous studies found a raised circulating VEGF in untreated
patients compared with treated patients and healthy controls,
and this elevation was correlated with the nocturnal hypoxia
and the apnea-hypopnea index.24,25
Contrary to our results, we did not ﬁnd increased VEGF levels
in a number of comorbidities that were possibly expected.
VEGF is described as being raised in vasculitis,4,26 but this was
not found in our study. However, our vasculitic neuropathies
were mostly limited to the peripheral nervous system with no
systemic involvement or associated inﬂammatory autoimmune
disease. In connective tissue diseases, VEGF is associated with
raised inﬂammatory cytokines and/or disease activity,27–29 and
very high circulating VEGF levels have been found in patients
with most active connective tissue diseases.27 In pulmonary
infection, circulating VEGF can be elevated,30,31 explaining
raised sVEGF in 2 cases of our cohort, 1 with pneumonia
(patient 233) and another with organizing pneumonitis (pa-
tient 142). Both of them had very elevated sVEGF, which
decreased after treatment. Solid cancers have been associated
with increased VEGF levels.7,32 VEGF levels correlate with
serum interleukin 6 (IL-6) (interesting in the context of IL-6
drive in POEMS, see below) and other cytokines, anemia,
advanced cancer stage, and poor prognosis.18,33–40
Fifteen of 168 non-POEMS NP patients had a raised sVEGF,
which could be explained by an identiﬁed comorbidity as
above: anemia with low serum iron (3/15, patients 81, 117,
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and 176), COPD or sleep apnea (2/15, patients 145 and 238),
connective tissue disease (3/15, patients 61, 100, and 44),
pulmonary infection (2/15, patients 142 and 233), and low-
grade non-Hodgkin lymphoma (NHL) (1/15, patient 114)
(table e-2, links.lww.com/NXI/A61). Retrospective data
collection did not identify a potential cause of raised sVEGF in
4/15 patients including 3 patients with anti-MAG NP re-
quiring further study.
VEGF upregulation by HIF-1-alpha and inﬂammatory cyto-
kines is shared by all these conditions. In the pathogenesis of
POEMS syndrome, VEGF is believed to be a key cytokine. It
is produced in all tissues. Its receptors are found mainly on
endothelial cells but also on hematopoietic stem cells, meg-
akaryocytes, monocytes, chondrocytes, and others. Its neo-
angiogenesis and vascular permeability functions are likely
responsible for some of the clinical features of POEMS, such
as edema, pleural eﬀusion, ascites, papilledema, and pulmo-
nary hypertension. Increased endoneurial microvascular per-
meability is thought to contribute to blood-nerve barrier
dysfunction, allowing ingress of toxic agents that cause nerve
damage.41 Its osteogenesis function may be involved in scle-
rotic bone lesion formation. Thrombocytosis and poly-
cythemia cause microvascular thrombosis and microvascular
neoangiogenesis, inducing hypoxia and stabilizing HIF-1-
alpha resulting in an upregulation of VEGF. High VEGF is
also sustained by inﬂammatory cytokines IL-1 beta, tumor
necrosis factor (TNF) alpha, and IL-6.5,7,17,32
This retrospective study conﬁrmed the high Se and Sp of
sVEGF as a useful biomarker for POEMS syndrome diagnosis
in patients with an NP, especially when associated with
a paraproteinemia. In this context, only few important con-
founding comorbidities were identiﬁed, which should be
considered during diagnosis. When clinical features are likely
those of POEMS syndrome (a rapidly progressive de-
myelinating sensorimotor distal polyneuropathy with lambda
light chain paraproteinemia), high VEGF is a very useful di-
agnostic biomarker for the diagnosis of POEMS syndrome,
and the other clinical and biological features of POEMS
syndrome should be systematically sought. On the contrary,
when an increased VEGF level is found without a paraprotein
and an appropriate NP, testing should be repeated, partic-
ularly after acute illnesses, and anemias with low iron, can-
cers, hematologic malignancies, OSAHS, COPD, vasculitis,
and chronic inﬂammatory diseases should be excluded be-
fore using VEGF conﬁdently for a POEMS diagnosis.
sVEGF can be sent for analysis to the Neuroimmunology
Department of the Institute of Neurology, Queen Square,
London, United Kingdom.
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